<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01783626</url>
  </required_header>
  <id_info>
    <org_study_id>1498</org_study_id>
    <nct_id>NCT01783626</nct_id>
  </id_info>
  <brief_title>Evaluation of Evodial Hemodialyzer Selectivity Modifications (Evodial +)</brief_title>
  <official_title>Evaluation of Evodial Hemodialyzer Selectivity Modifications (Evodial +) - A Prospective, Monocenter, Open and Non-randomized Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gambro Lundia AB</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Baxter Healthcare Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evodial +hemodialyzer consists of an evolution of the existing CE marked Evodial device, with&#xD;
      respect to the hemodialyzer membrane removal characteristics. Different membrane prototypes&#xD;
      configurations are proposed (3 versions in total), with the objective to modulate the&#xD;
      hemodialyzer removal capacities (convective and adsorptive capacities).&#xD;
&#xD;
      Materials(including heparin grafted specifications) as well as the sterilization process are&#xD;
      identical to the Evodial hemodialyzer. Based on available preclinical data , a clinical study&#xD;
      is requested to document in vivo the different prototypes removal capacities with respect to&#xD;
      middle Molecular Weight (MW) reference toxins such as b2 Microglobulin and collect data with&#xD;
      regards to protein loss.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: Beta 2 Microglobulin elimination</measure>
    <time_frame>Change from T0 (dialysis start) at T4 hours (dialysis stop)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy: -Elimination of Myoglobin,alpha 1 Microglobulin, alpha amylase and Factor D</measure>
    <time_frame>Change from T0 (dialysis start) at T 4hours (dialysis stop)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy:Profile of ultrafiltrated proteins</measure>
    <time_frame>at T4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Follow-up of all AEs/SAEs</measure>
    <time_frame>during the study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Measurement of Albumin loss</measure>
    <time_frame>At T4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Cumulative Purified volume (Kt)</measure>
    <time_frame>At T4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Total protein</measure>
    <time_frame>Change from T0 and T4 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>End Stage Renal Disease (ESRD)</condition>
  <arm_group>
    <arm_group_label>Evodial</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Period I: HDF post dilution Total Volume 8 liters : 1 HD session (2nd HD of the week) Period II: HDF post dilution Total Volume 20 liters : 1 HD session (2nd HD of the week)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evodial+ Condition B1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period I: HDF post dilution Total Volume 8 liters : 1 HD session (2nd HD of the week) Period II: HDF post dilution Total Volume 20 liters : 1 HD session (2nd HD of the week)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evodial+ Condition B2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period I: HDF post dilution Total Volume 8 liters : 1 HD session (2nd HD of the week) Period II: HDF post dilution Total Volume 20 liters : 1 HD session (2nd HD of the week)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evodial+ Condition C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period I: HDF post dilution Total Volume 8 liters : 1 HD session (2nd HD of the week) Period II: HDF post dilution Total Volume 20 liters : 1 HD session (2nd HD of the week)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Evodial</intervention_name>
    <arm_group_label>Evodial</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Evodial+ Condition B1</intervention_name>
    <arm_group_label>Evodial+ Condition B1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Evodial+ Condition B2</intervention_name>
    <arm_group_label>Evodial+ Condition B2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Evodial+ Condition C</intervention_name>
    <arm_group_label>Evodial+ Condition C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Anuric patient (diuresis&lt;300ml) ,&#xD;
&#xD;
          2. ESRD patient treated for at least 3 months,&#xD;
&#xD;
          3. Patient treated in HDF post-dilution,&#xD;
&#xD;
          4. Vascular access functioning properly (Qb &gt; 250 ml/min),&#xD;
&#xD;
          5. Patient aged 18 years or more,&#xD;
&#xD;
          6. Written consent to participate in the study (informed consent).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient with pre-dialytic albuminemia &lt;3.3 g/dl(Nephelometry assay)&#xD;
&#xD;
          2. Patient with known allergy to heparin or type II heparininduced thrombocytopenia (HIT&#xD;
             type II);&#xD;
&#xD;
          3. Patient under guardianship;&#xD;
&#xD;
          4. Women pregnant or breast feeding;&#xD;
&#xD;
          5. Patient included in other studies that could interfere with the goals of the current&#xD;
             study.&#xD;
&#xD;
          6. Patient that are not affiliated to the health system(beneficiary or dependent).&#xD;
&#xD;
          7. Patient with positive serology (HIV, Hepatitis).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathalie Loughraieb</last_name>
    <role>Study Director</role>
    <affiliation>Gambro Industries</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HÃ´pital Louis-Pasteur (Cherbourg-Octeville)</name>
      <address>
        <city>Cherbourg-Octeville</city>
        <zip>50102</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>January 28, 2013</study_first_submitted>
  <study_first_submitted_qc>February 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2013</study_first_posted>
  <last_update_submitted>May 5, 2017</last_update_submitted>
  <last_update_submitted_qc>May 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

